Ventyx Biosciences’ (VTYX) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Ventyx Biosciences (NASDAQ:VTYX) in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a $6.00 price objective on the stock. HC Wainwright also issued estimates for Ventyx Biosciences’ Q4 2024 earnings at ($0.59) EPS, FY2024 earnings at ($2.14) EPS and FY2025 earnings at ($2.93) EPS.

A number of other analysts have also weighed in on VTYX. Wells Fargo & Company dropped their price objective on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Canaccord Genuity Group dropped their price objective on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.29.

Ventyx Biosciences Price Performance

Shares of VTYX opened at $2.54 on Tuesday. The firm has a market cap of $179.50 million, a P/E ratio of -0.91 and a beta of 0.36. The stock has a 50 day simple moving average of $2.19 and a two-hundred day simple moving average of $3.10. Ventyx Biosciences has a 1 year low of $1.79 and a 1 year high of $17.65.

Ventyx Biosciences (NASDAQ:VTYX) last issued its earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.12. On average, equities analysts anticipate that Ventyx Biosciences will post -2.14 earnings per share for the current year.

Hedge Funds Weigh In On Ventyx Biosciences

A number of institutional investors have recently added to or reduced their stakes in VTYX. Farallon Capital Management LLC bought a new position in Ventyx Biosciences in the first quarter worth $17,435,000. Deerfield Management Company L.P. Series C raised its holdings in Ventyx Biosciences by 64.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock worth $13,466,000 after purchasing an additional 2,287,570 shares in the last quarter. Redmile Group LLC raised its holdings in Ventyx Biosciences by 944.4% in the first quarter. Redmile Group LLC now owns 2,164,126 shares of the company’s stock worth $11,903,000 after purchasing an additional 1,956,923 shares in the last quarter. First Light Asset Management LLC bought a new position in Ventyx Biosciences in the first quarter worth $3,437,000. Finally, Ikarian Capital LLC raised its holdings in Ventyx Biosciences by 8,483.8% in the first quarter. Ikarian Capital LLC now owns 507,647 shares of the company’s stock worth $2,792,000 after purchasing an additional 501,733 shares in the last quarter. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.